Literature DB >> 1665684

Immunohistochemical differentiation between ovarian granulosa cell tumors and ovarian carcinomas.

G Gitsch1, P Kohlberger, E Hanzal, H Kölbl, G Breitenecker.   

Abstract

Differential diagnosis is a major problem in histopathology of ovarian tumors. Difficulties may arise if the tumor is a poorly differentiated carcinoma or a granulosa cell tumor of the sarcomatoid type. It was the aim of the present study to evaluate the usefulness of immunohistochemistry in differentiating between granulosa cell tumors of the ovary and ovarian carcinomas. We investigated 56 ovarian malignancies (13 granulosa cell tumors, 17 serous, 14 mucinous and 12 poorly differentiated carcinomas) and performed immunohistochemical detection of Vimentin, Keratin, CA125, CA19-9, CEA, S100 and Ber-EP4. Expression of Vimentin was highest and expression of Keratin was lowest in granulosa cell tumors in contrast to carcinomas. CA125 and CA19-9 were not expressed in granulosa cell tumors, whereas the detection rate in carcinomas (except for CA125 in mucinous carcinomas) was high. CEA, S100 and Ber-EP4 do not seem to be useful markers in differential diagnosis. A marker profile of Vimentin, Keratin, CA125 and CA19-9 allows a quite strict differentiation between poorly differentiated ovarian carcinomas and granulosa cell tumors of the ovary.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665684     DOI: 10.1007/bf02390384

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  15 in total

1.  Cytokeratin expression in smooth muscle and smooth muscle tumours.

Authors:  D C Brown; J M Theaker; P M Banks; K C Gatter; D Y Mason
Journal:  Histopathology       Date:  1987-05       Impact factor: 5.087

2.  Cytokeratin-specific monoclonal antibodies are reactive with tumours of smooth muscle derivation. An immunocytochemical and biochemical study using antibodies to intermediate filament cytoskeletal proteins.

Authors:  A J Norton; J A Thomas; P G Isaacson
Journal:  Histopathology       Date:  1987-05       Impact factor: 5.087

3.  A soluble protein characteristic of the nervous system.

Authors:  B W Moore
Journal:  Biochem Biophys Res Commun       Date:  1965-06-09       Impact factor: 3.575

Review 4.  Contributions of immunocytochemistry to the diagnosis and study of ovarian neoplasms.

Authors:  R J Kurman; P Ganjei; M Nadji
Journal:  Int J Gynecol Pathol       Date:  1984       Impact factor: 2.762

Review 5.  Ovarian sex cord-stromal tumors: recent progress.

Authors:  R H Young; R E Scully
Journal:  Int J Gynecol Pathol       Date:  1982       Impact factor: 2.762

6.  Detection of S-100 labelled cells in nasopharyngeal carcinoma.

Authors:  L Lauriola; F Michetti; S Sentinelli; D Cocchia
Journal:  J Clin Pathol       Date:  1984-11       Impact factor: 3.411

7.  Desmosomal plaque-associated vimentin filaments in human ovarian granulosa cell tumors of various histologic patterns.

Authors:  B Czernobilsky; R Moll; G Leppien; G Schweikhart; W W Franke
Journal:  Am J Pathol       Date:  1987-03       Impact factor: 4.307

8.  Elevated serum alpha-fetoprotein associated with Sertoli-Leydig cell tumors of the ovary.

Authors:  W J Mann; J Chumas; Z Rosenwaks; J A Merrill; D Davenport
Journal:  Obstet Gynecol       Date:  1986-01       Impact factor: 7.661

9.  Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.

Authors:  W Neunteufel; G Breitenecker
Journal:  Gynecol Oncol       Date:  1989-03       Impact factor: 5.482

10.  Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas.

Authors:  H M Davis; V R Zurawski; R C Bast; T L Klug
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more
  1 in total

1.  Expression of cytokeratins in granulosa cell tumors and ovarian carcinomas.

Authors:  G Gitsch; P Kohlberger; A Steiner; B Neumeister; G Breitenecker
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.